Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Immunovant, Inc. (IMVT)

Immunovant IMVT-1402 met primary endpoint in RA trial; quarterly loss $97.2 million

Mixed Impact 4 of 5 product/contract

Immunovant reported that IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 in Period 2 of a potentially registrational trial in difficult-to-treat rheumatoid arthritis, with FDA discussions planned later this year on the path forward. The company also said it is unlikely to advance IMVT-1402 further in Sjogren's disease beyond the ongoing Phase 2 trial, while its net loss narrowed and cash declined over the period.

Key points

  • IMVT-1402 600 mg ACR20 response at Week 28 was 92.5% vs. 75.6% for placebo (p=0.0139); the 300 mg arm did not differ from placebo.
  • FDA discussions are planned for later this year on the registrational program in difficult-to-treat rheumatoid arthritis.
  • Net loss for the quarter ended September 30, 2026 was $97.2 million ($0.47 per share), vs. $126.5 million ($0.73 per share) a year earlier; cash and equivalents were $722.3 million, down from $902.1 million at March 31, 2026.

The filing

CompanyImmunovant, Inc. (IMVT)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:09 AM ET
Accession number0001764013-26-000121

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.